Drug development for neurodegenerative diseases is struggling with one of its most intractable barriers: the slow, variable, and subjective nature of clinical endpoints Traditional assessment scales, ...

When you go for a walk, how does your brain know the difference between a parked car and a moving car? This seemingly simple distinction is challenging because eye movements, such as the ones we make ...